GSK 重金打造14種明星藥 !!!

GSK aims for 14 drug candidates in pivotal trials over next two years  By WRAL Tech Wire Updated Dec. 3, 2012 at 5:26 p.m.RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline (NYSE: GSK) has big plans to bring new life its product suite. In London on Monday, GSK executives laid out an aggressive agenda to investors and analysts - 14 drug candidates to pivotal clinical trial over next two years. Among those are products that could "change the way cancer and heart disease are treated," Reuters reported. However, GSK Chief Executive Officer Andrew Witty's team at the drug giant aren't focusing on so-called blockbusters as in years past, Reuters noted.GSK is "now developing a broader range of drugs than in the past, as it moves away from the industry's traditional focus on blockbusters," Reuters reported.A "handful have the potential to become multibillion-dollar-a-year sellers," the wire service added."We feel very comfortable, particularly through 2013 and into 2014, that we can manage both with a broadly flat R&D budget and also without significant increases in our commercial organization," Reuters quoted Witty as saying. Phase 3 clinical trials in 2013 and 2014 are likely to include heart drug candidate darapladib and therapeutic cancer vaccine MAGE-A3, Reuters noted.